---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-282502"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:31:57.768593+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IO Biotech secures up to €57.5M EIB debt facility; extends cash runway into Q2 2026

## Summary
- Total committed tranches of €37.5M (Tranche A €10M, B €12.5M, C €15M) plus €20M uncommitted accordion.
- First two tranches expected for disbursement in Q1 2025; each tranche matures in 6 years at 8% fixed interest.
- Tranche C requires $50M cash raise and US or EU marketing authorization submission for IO102-IO103 within 36 months.
- Warrants to be issued to EIB upon each tranche disbursement; loan is unsecured with no minimum cash covenants.
- Cash runway now expected into Q2 2026, funding ongoing clinical trials and pre-commercialization activities.

## SEC filing metadata
- accession: 0001193125-24-282502
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312524282502/0001193125-24-282502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312524282502/d815097d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-282502
- JSON: https://secwatch.observer/filing/0001193125-24-282502.json
- Plain text: https://secwatch.observer/filing/0001193125-24-282502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.